Building the First CAR T Company

Key takeaways

CAR-T therapy represents a groundbreaking advancement in cancer treatment, particularly for childhood leukemias.
The patient journey in CAR-T therapy is complex, involving a detailed process of T-cell harvesting, engineering, and reinfusion.
Building a CAR-T company requires a fully integrated approach, with a focus on manufacturing, logistics, and organizational culture.
Innovations in T-cell engineering are critical for overcoming current limitations and expanding treatment options for solid tumors.
Navigating regulatory challenges and achieving reimbursement for new therapies is crucial for market acceptance and success.
Collaboration, humility, and the right team are fundamental for entrepreneurs driving innovation in the biotech space.

Summary

Introduction to CAR-T Therapy

The episode kicks off with a discussion about CAR-T therapy, a revolutionary treatment utilizing engineered T cells that has shown remarkable success in treating childhood leukemias. The hosts, alongside Oz Azam, explain the fundamentals of CAR-T, emphasizing the unique role T cells play in identifying and attacking cancer cells.

The Patient and Cell Journey

Listeners are taken through the patient journey, particularly focusing on a child diagnosed with leukemia. The narrative outlines how T cells are harvested, re-engineered, and infused back into patients. This section details the step-by-step process involved in CAR-T therapy, from blood collection to monitoring for the successful response post-infusion.

Building a CAR-T Company

Oz Azam discusses the complexities of building a company around CAR-T therapy. Tackling unique challenges such as manufacturing and logistics, he emphasizes the necessity of a fully integrated approach in managing the entire journey from patient to product. Insights into organizational culture, team dynamics, and the agility required in a startup environment are shared.

Technological Innovations and Future Directions

Emerging technologies in T-cell engineering are explored, including the potential for multi-target therapies for complex cancers. The conversation elaborates on advancements such as gene editing, which could expand the capabilities of CAR-T therapy and lower associated costs, paving the way for broader accessibility.

Regulatory Hurdles and Market Acceptance

The hosts address the hurdles potential therapies face in gaining acceptance in the clinical environment, emphasizing the significance of navigating regulatory landscapes and achieving reimbursement from healthcare systems. The evolution of reimbursement models is highlighted, suggesting a shift towards performance-based payments for new therapies.

Lessons Learned and Future Outlook

The episode concludes with reflections on the journey of growth and development within the CAR-T space. Key lessons around hiring, network building, humility, and the importance of collaboration in advancing medical innovation are emphasized, alongside the ambitious goal of making these therapies accessible to a wider range of cancer patients.

Show notes

with @OzAzamTmunity1, @JorgeCondeBio, and @omnivorousread

CAR T therapy, the groundbreaking new medicines that uses engineered T-cells to attack cancer, has been so effective in childhood leukemias that we believe it may actually be a potential cure. But this isn't just one new medicine, it's an entirely new therapeutic tool—and a total paradigm shift from most traditional medicines we've seen before.

Tmunity CEO Usman "Oz" Azam was previously the head of Cell and Gene Therapies at Novartis, in many ways the first CAR T company and the team brought us blood cancer CAR T-cell therapy Kymriah—the first cell-based gene therapy to be approved in the US. In this conversation, Azam discusses with a16z's general partner Jorge Conde and Hanne Tidnam what CAR T therapy really is and how it all works. The conversation begins with the “patient and cell journey” of this treatment and how this medicine is developed, manufactured, delivered to patients; why exactly it's so different traditional medicines; what it will take to make these new medicines work on more kinds of cancer, scale to more patients, and cost less; and finally, what company building lessons can be learned from building the first CAR T company of its kind from the ground up.

This episode was recorded at the annual a16z Summit.

Stay Updated:

Find a16z on YouTube: YouTube

Find a16z on X

Find a16z on LinkedIn

Listen to the a16z Show on Spotify

Listen to the a16z Show on Apple Podcasts

Follow our host: https://twitter.com/eriktorenberg

Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.